Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

BTIG analyst Marie Thibault reiterated a Buy rating on Masimo (MASI – Research Report) today and set a price target of $178.00. The company’s ...

Masimo Corp. today announced Katie Szyman as its new chief executive, effective Feb. 12. Szyman is currently worldwide ...

Today the Board of Directors (the "Board") of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the ...

Our mission is to improve life, improve patient outcomes; and reduce the cost of care. Masimo SET ® Measure-through Motion and Low Perfusion ™ pulse oximetry, introduced in 1995, has been shown in ...

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an ...

The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional ...